1. Basal Cell Carcinoma: A Comprehensive Review
- Author
-
Emanuela Marcelli, Elena Campione, Manuela Ferracin, Barbara Bortolani, Emi Dika, Elisabetta Broseghini, Federica Scarfì, Costantino Ricci, Mattia Riefolo, Martina Lambertini, Dika E., Scarfi F., Ferracin M., Broseghini E., Marcelli E., Bortolani B., Campione E., Riefolo M., Ricci C., and Lambertini M.
- Subjects
Pyridines ,Review ,Sonidegib ,lcsh:Chemistry ,030207 dermatology & venereal diseases ,chemistry.chemical_compound ,0302 clinical medicine ,vismodegib ,Anilides ,skin and connective tissue diseases ,lcsh:QH301-705.5 ,Spectroscopy ,integumentary system ,microRNA ,treatment ,General Medicine ,Phenotype ,Hedgehog signaling pathway ,Computer Science Applications ,030220 oncology & carcinogenesis ,hedgehog pathway inhibitors ,medicine.drug ,animal structures ,Vismodegib ,Biology ,Catalysis ,Hedgehog pathway inhibitor ,Inorganic Chemistry ,03 medical and health sciences ,Settore MED/35 ,basal cell carcinoma ,medicine ,Carcinoma ,Humans ,Basal cell carcinoma ,Hedgehog Proteins ,Physical and Theoretical Chemistry ,Molecular Biology ,neoplasms ,sonidegib ,Mechanism (biology) ,Organic Chemistry ,fungi ,Biphenyl Compounds ,medicine.disease ,MicroRNAs ,chemistry ,lcsh:Biology (General) ,lcsh:QD1-999 ,Carcinoma, Basal Cell ,Drug Resistance, Neoplasm ,Cancer research ,genetic - Abstract
Basal cell carcinoma (BCC) is the most common type of carcinoma worldwide. BCC development is the result of a complex interaction between environmental, phenotypic and genetic factors. However, despite the progress in the field, BCC biology and mechanisms of resistance against systemic treatments have been poorly investigated. The aim of the present review is to provide a revision of BCC histological and molecular features, including microRNA (miRNA) dysregulation, with a specific focus on the molecular basis of BCC systemic therapies. Papers from the last ten years regarding BCC genetic and phenotypic alterations, as well as the mechanism of resistance against hedgehog pathway inhibitors vismodegib and sonidegib were included. The involvement of miRNAs in BCC resistance to systemic therapies is emerging as a new field of knowledge.
- Published
- 2020